Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of acute myeloid leukaemia (AML) called core-binding factor AML (CBF-AML), confirmed through genetic or chromosome testing showing particular gene fusions
• People whose leukaemia has certain high-risk gene changes, complex chromosomal patterns, or whose disease was still detectable through specialised testing (MRD) after two rounds of chemotherapy
• People whose diagnosis has been thoroughly assessed and confirmed as CBF-AML — not a transformed or treatment-related form of AML
• People aged 18 to 64 years old
• People whose liver and kidney function results fall within acceptable ranges (blood bilirubin, liver enzymes, and creatinine levels must meet specific thresholds)
• People with normal heart function, based on heart scans and a standard heart function classification (confirm with trial site)
• People who have a general physical fitness score of 0, 1, or 2 on a standard scale used by doctors to assess overall health (ECOG score)
• People whose white blood cell count was below a certain level at diagnosis and who have not received any chemotherapy beforehand, except for a specific tablet called hydroxyurea
• People whose white blood cell count was at or above a certain level at diagnosis and who have only received hydroxyurea or a specific chemotherapy drug (cytarabine) beforehand
• Women who are not pregnant and not breastfeeding
• Women of childbearing age who have had a pregnancy test to confirm they are not pregnant
• People (or their family members) who have signed a form giving informed consent to participate

Who may not be able to join:

• People whose AML developed from another blood condition (MDS), or whose AML was caused by previous cancer treatment, or who have a mixed-cell type of leukaemia, or who had leukaemia spread to the nervous system or other areas outside the bone marrow at the time of diagnosis
• People whose AML has come back after a previous remission (relapsed AML)
• People who have a known allergy or medical reason to avoid any of the drugs used in this trial
• People whose liver or kidney function results fall outside the acceptable ranges for this trial
• People with certain heart conditions, including reduced heart pumping function, significant heart failure, fluid around the heart, a recent heart attack within the past six months, or an abnormal heart rhythm reading on an ECG (confirm with trial site for specific thresholds)
• People with certain lung conditions, including fluid on the lungs or around the lungs above a certain severity level
• People who currently have another type of cancer in another part of the body
• People who have active hepatitis A, B, or C, active tuberculosis, or who are HIV-positive
• People who have other blood disorders unrelated to their leukaemia, including certain clotting problems
• People who are unable to understand or follow the requirements of the study
• People who are already taking part in another clinical trial, or who have any other condition that would make participation in the study unsuitable

Important: Always verify eligibility with the trial site directly before applying.